Webinar: Boron Neutron Capture Therapy - Today's Use and Future Aspects

แชร์
ฝัง
  • เผยแพร่เมื่อ 29 มี.ค. 2022
  • This is a recording of a live webinar hosted by Cosylab on March 2nd 2022.
    Speakers:
    Jay Flanz, PhD, President and Chair of the Particle Therapy CoOperative Group international organization (PTCOG), Retired assoc. Prof. at the Harvard Medical School, Retired Technical Director at the Francis H. Burr Proton Therapy Center of the Massachusetts General Hospital
    Paul Busse, MD, PhD, Joseph W. Cotchett Endowed Chair in Radiation Oncology, Massachusetts General Hospital
    Wolfgang Sauerwein, Prof. Dr. med., BNCT Global GmbH, Heinrich Heine University Dusseldorf, President of the German Society for Boron Neutron Capture Therapy
    Thomas Rock Mackie, PhD, Emeritus Professor, University of Wisconsin,
    Board Chairman and Co-Founder of Leo Cancer Care
    Hanna Koivunoro, PhD, Chief Medical Physicist at Neutron Therapeutics Inc.
    Akira Matsumura, M.D. Ph.D. Dr.med, President, Ibaraki Prefectural University of Health Sciences, Emeritus Professor, Faculty of Medicine, University of Tsukuba, Japan
    Toshinori Mitsumoto, Principal Engineer at Sumitomo Heavy Industries
    Elizabeth Reczek, PhD, Chief Executive Officer at Neutron Therapeutics, Inc.
    Seppo Pakala, Chief Medical Officer at Neutron Therapeutics Inc.
    Niek Schreuder, PhD, Chief Scientific Officer at LEO Cancer Care
  • วิทยาศาสตร์และเทคโนโลยี

ความคิดเห็น • 1

  • @remypourteau9877
    @remypourteau9877 ปีที่แล้ว +1

    0:42 Introduction
    2:10 Opening remarks
    7:14 An overview of and Historical Review on BNCT
    Part1: Clinical aspects of BNCT
    33:26 P1.a: The path of BNCT to a reimbursement
    50:04 P1.b: Imaging and patient positioning
    1:03:33 P1.c: Treatment Planning for BNCT
    1:27:02 P1.d: Status of BNCT in Japan
    Part2: Industrial aspects of BNCT
    1:44:10 P2.a: Sumitomo Heavy Industries Presentation
    1:58:19 P2.b: Neutron Therapeutics presentation
    2:11:36 P2.c: Recent BNCT drug development and use overview
    2:22:00 P2.d: TAE Life Sciences presentation
    2:43:00 Conclusion